Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02781844 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism
A Phase 1 study, sponsored by Shire.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT02781844 is a Phase 1 study that has completed, run by Shire. The registered enrollment target is 34 participants.
The verdict
NCT02781844, a Phase 1 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This study is being conducted to characterize the effects of twice daily administration of rhPTH(1-84) on the way the body handles rhPTH(1-84) as well as its actions and safety and tolerability over the course of 24 hours as compared with the current once daily dosing regimen of marketed rhPTH(1-84) (marketed in the United States as Natpara® and in the EU as Natpar).
Interventions
- DRUG 25mcg rhPTH(1-84)
- DRUG 50mcg rhPTH(1-84)
- DRUG 100mcg rhPTH(1-84)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2017-04-03 |
| Est. Completion | 2019-03-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02781844
The ClinicalTrials.gov registry entry for NCT02781844 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 25mcg rhPTH(1-84) is the first listed.
NCT02781844 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02781844 about?
NCT02781844 is a clinical study titled "Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism". This study is being conducted to characterize the effects of twice daily administration of rhPTH(1-84) on the way the body handles rhPTH(1-84) as well as its actions and safety and tolerability over the course of 24 hours as compared with the current once daily dosing regimen of marketed rhPTH(1-84)...
What is the current status of trial NCT02781844?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2017-04-03. Estimated completion is 2019-03-08.
What interventions are being tested in trial NCT02781844?
The interventions under investigation include: 25mcg rhPTH(1-84) (DRUG), 50mcg rhPTH(1-84) (DRUG), 100mcg rhPTH(1-84) (DRUG).
Who is sponsoring clinical trial NCT02781844?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.